FinancialBuzz.com’s latest Buzz on the Street Show: Featuring Our Corporate News Recap on “Love Hemp New Product Development Update.”
World High Life PLC (OTCQB: WRHLF) (AQSE: LIFE) is pleased to announce that its wholly owned subsidiary, Love Hemp Ltd (“Love Hemp“), continues to focus on new product development to drive sales growth and reach customers. The importance of the Love Hemp brand’s ability to be flexible and agile whilst responding to consumer needs has never been more apparent, with Love Hemp Immune launching six-months ahead of schedule, whilst the brand’s global online retailer, CBDOilsUK has expanded its portfolio with the launch of one of the most affordable collections of CBD capsules and oils available to-date, 2020 Botanics.
World High Life was established by the founders of Supreme Cannabis, and 1933 Industries, both companies at the forefront of the legalized cannabis industry. LIFE was established to take advantage of the huge opportunities available in the UK and European legal cannabis space, which is set to be the largest in the world within five years.
While cannabis legalization is rapidly spreading, the plant is still considered a Schedule 1 controlled substance under federal regulations. And despite medical breakthroughs, there is still concern over the broad use of cannabis. Regulators are worried about the potential abuse of marijuana, which is a plant within the cannabis family. There is greater concern with the marijuana counterpart mainly because of its main active ingredient: THC or tetrahydrocannabinol, which is typically known to cause psychoactive effects on its consumers. However, with ongoing clinical trials and research, health officials have begun to realize that cannabis can be used as a potential medical treatment. Following the emergence of the legal cannabis market, the number of users steadily began to rise. Principally, most consumers are medical patients using cannabis to ease symptoms related with cancer, HIV/AIDS, multiple sclerosis, epilepsy, Alzheimer’s, Parkinson’s, and chronic pain. As a result, the global marijuana market is expected to grow from USD 42.20 Billion in 2017 to USD 466.81 Billion by 2025 while registering a CAGR of 35.3%, according to data compiled by Verified Market Intelligence.
Overall, there are hundreds of studies being conducted to evaluate the efficacy of CBD. Notably, researchers are advancing studies to further promote the use of CBD for Parkinson’s treatment. Currently, the research on CBD for Parkinson’s is very limited and most studies are likely small-scale trials. However, the handful of studies that have been conducted suggest that CBD can have positive effects when dealing with nonmotor symptoms. For example, Rachel Dolhun, MD, Vice President, Medical Communications at The Michael J. Fox Foundation for Parkinson’s Research explained that “the work to date on marijuana and cannabinoids has given promising but conflicting signals on potential benefit for motor and non-motor symptoms as well as levodopa-induced dyskinesia. This therapy may represent a future treatment option for PD, but the correct dose and formulation are not clear, full side effects and drug interactions are unknown, and benefits have not been rigorously determined. Future studies should be large and well designed to provide clear data on the safety and efficacy of marijuana and cannabinoids in Parkinson’s.”
For more information, please visit: World High Life Plc
For more corporate news on World High Life Plc, check out the Buzz on the Street
About Buzz on the Street: One of FinancialBuzz.com’s latest corporate and financial news shows, covering the latest trending stock market news. Buzz on the Street looks to become a leader in corporate video news dissemination. Buzz on the Street is 100% original content, brought to you by Financial Buzz Media.